Overview

Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer

Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
0
Participant gender:
All
Summary
Multicenter, prospective, randomized studies.Evaluation of the sensitivity to different chemotherapy regimens in platinum-partial sensitive recurrent ovarian cancer based on 11 gene tests of homologous recombination pathway.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hunan Cancer Hospital
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Doxorubicin
Liposomal doxorubicin
Paclitaxel
Criteria
Inclusion Criteria:

1. age: 18-75 years old

2. PS score: ECOG 0 ~ 2

3. histopathologically confirmed primary high-grade serous adenocarcinoma or high-grade
endometrioid adenocarcinoma of the ovary, fallopian tube or peritoneum;

4. the time interval between this recurrence and the last chemotherapy was 6-12 months;

5. evaluate the ability of bone marrow, liver, kidney, heart and other important organ
functions to withstand chemotherapy;

6. expected survival over 3 months;

7. sign the informed consent.

Exclusion Criteria:

1. brain metastasis or the presence of symptoms caused by brain metastasis;

2. serious complications;

3. acute inflammatory reaction;

4. other tumors;

5. a history of allergy to paclitaxel or polyropyridone liposomes;